Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status:
Terminated
Trial end date:
2018-03-29
Target enrollment:
Participant gender:
Summary
The available data indicate that Ceritinib has substantial anti-tumor activity in patients
with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC).
This trial will investigate the potential of Ceritinib in patients with advanced
gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no
available therapeutic option.